EphB inhibitors are a class of chemical compounds that specifically target and modulate the activity of the EphB receptors, which are a subset of the Eph receptor family. Eph receptors are a large family of receptor tyrosine kinases that play a key role in cell-cell communication, particularly in processes involving cell adhesion, migration, and boundary formation. EphB receptors, in particular, are activated by ephrin-B ligands through cell-cell contact, resulting in bidirectional signaling where both the receptor-expressing and ligand-expressing cells receive signals. Inhibitors of EphB receptors are typically small molecules designed to disrupt this signaling cascade, either by directly binding to the receptor's kinase domain or by interfering with the ephrin-binding site. These inhibitors can vary widely in their chemical structures, often incorporating aromatic rings, heterocycles, or other scaffolds that allow them to interact specifically with the active sites or allosteric sites of the EphB receptors.
Structurally, EphB inhibitors are characterized by their ability to penetrate cell membranes and selectively bind to their target receptors. Many of these inhibitors act as ATP-competitive molecules, competing with ATP for binding to the kinase domain of EphB receptors and thus preventing receptor autophosphorylation and subsequent downstream signaling. Alternatively, some inhibitors function through non-ATP-competitive mechanisms, stabilizing the receptor in an inactive conformation or preventing the binding of ephrin ligands. The chemical diversity of EphB inhibitors allows for the modulation of their binding affinities, selectivity, and activity profiles. In the study of EphB signaling, these inhibitors serve as essential tools for understanding the biological functions of EphB receptors and their role in cellular processes such as development, axon guidance, and tissue organization. Understanding the molecular interactions and specificity of EphB inhibitors is crucial for advancing knowledge in cell biology and signaling pathways mediated by Eph receptors.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, when incorporated into DNA, could hypothetically downregulate EphB transcription by the demethylation of gene promoter regions, thus altering gene expression patterns. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, as a tyrosine kinase inhibitor, may specifically target kinases responsible for EphB activation, resulting in a decrease in EphB signal transduction and subsequent expression. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin could theoretically hamper EphB expression by inhibiting the phosphorylation of enzymes upstream of EphB, thereby reducing the transcriptional initiation of its gene. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol may suppress EphB receptor expression by hindering the activation of specific transcription factors that are essential for the EphB gene's transcriptional activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin could downregulate EphB expression by hindering nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which might be crucial for EphB gene expression. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
DL-Sulforaphane might reduce the transcriptional activity of the EphB gene by altering histone deacetylase (HDAC) activity, which could change chromatin structure and gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 may decrease EphB expression by directly inhibiting phosphoinositide 3-kinases (PI3Ks), leading to a reduction in the PI3K/Akt signaling pathway that can control gene expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 could reduce the level of EphB protein by specifically inhibiting MEK1/2, thereby decreasing the activity of the MAPK/ERK pathway, a potential regulator of EphB expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 may lead to a decrease in EphB expression by specifically targeting c-Jun N-terminal kinase (JNK), which could be involved in the transcriptional control of the EphB gene. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 has the potential to downregulate EphB expression by targeting MEK, thereby suppressing the activation of the downstream ERK pathway, which may be involved in EphB gene expression. | ||||||